Skip to Content

DexCom Inc DXCM

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Capital Allocation

PREMIUM

Dexcom Prepares for G7 Launch in Europe; Raising Our FVE

Debbie S. Wang Senior Equity Analyst

Analyst Note

| Debbie S. Wang |

Dexcom posted another quarter of strong growth, seemingly unaffected by the COVID-19 ebbs and flows. We’ve raised our fair value estimate to $315 per share, up from $286, after inching up our projections to reflect expansion into some smaller European countries and Japan, as well as the ongoing shift toward direct distribution. Even with this boost to our intrinsic value, shares remain overvalued, from our perspective. Though Dexcom has yet to dig a moat, we’ve been impressed with the firm’s ability to consistently improve its technology. From the development of a simplified, more user-friendly continuous glucose monitor for certain countries new to continuous glucose monitors to the imminent European approval of G7, Dexcom has been able to build on its historical strength in accuracy and superior sensors. The firm has also displayed a nimbleness in reacting to competitive pressure from Abbott’s Freestyle Libre and Medtronic’s Guardian Connect CGM. Although the latter two firms have a ways to go to catch up to Dexcom on sensors and accuracy, Dexcom is clearly intent on pressing its advantage and solidifying its head start. As Dexcom works on integrating its CGM and software with various insulin pumps, diabetes management apps, and payer-sponsored disease management programs, we think there could be potential for switching costs and/or intangible assets to emerge and support a moat.

Read Full Analysis

Company Profile

Business Description

Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.

Contact
6340 Sequence Drive
San Diego, CA, 92121
T +1 858 200-0200
Sector Healthcare
Industry Medical Devices
Most Recent Earnings Sep 30, 2021
Fiscal Year End Dec 31, 2021
Stock Type Speculative Growth
Employees 6,400